Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Medullary Thyroid Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02268734
What this trial is testing

Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib

Who this might be right for
Metastatic Sporadic Medullary Thyroid Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 36
Testing effectiveness (Phase 2)Study completedNCT01164176
What this trial is testing

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Yonsei University 40
Large-scale testing (Phase 3)Study completedNCT01298323
What this trial is testing

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Who this might be right for
Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid Cancer
Sanofi 205
Testing effectiveness (Phase 2)UnknownNCT01118065
What this trial is testing

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Leiden University Medical Center 42
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Not applicableActive Not RecruitingNCT04970134
What this trial is testing

Spanish Study for Molecular Characterization of Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid CarcinomaMedullary Thyroid Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello 150
Testing effectiveness (Phase 2)Study completedNCT00027820
What this trial is testing

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Who this might be right for
Adult Acute Myeloid Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in Remission+27 more
Fred Hutchinson Cancer Center 106
Not applicableApproved For MarketingNCT01683110
What this trial is testing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Exelixis
Early research (Phase 1)Study completedNCT03246659
What this trial is testing

Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC

Who this might be right for
Medullary Thyroid Carcinoma
Paola Anna Erba 16
Early research (Phase 1)Not Yet RecruitingNCT07252661
What this trial is testing

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, Medullary+6 more
AccSalus Biosciences, Inc. 40
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Study completedNCT03587662
What this trial is testing

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Metastatic Kidney Medullary CarcinomaMetastatic Renal Cell CarcinomaSMARCB1 Negative+2 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT00100828
What this trial is testing

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 6
Not applicableApproved For MarketingNCT04204928
What this trial is testing

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid Cancer
Blueprint Medicines Corporation
Large-scale testing (Phase 3)Study completedNCT00704730
What this trial is testing

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Exelixis 330
Early research (Phase 1)Active Not RecruitingNCT02496208
What this trial is testing

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Who this might be right for
Bladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaBladder Urothelial Carcinoma+27 more
National Cancer Institute (NCI) 152
Testing effectiveness (Phase 2)Study completedNCT03072160
What this trial is testing

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer (MTC)
National Cancer Institute (NCI) 17
Testing effectiveness (Phase 2)Study completedNCT01625520
What this trial is testing

SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Federico II University 19
Testing effectiveness (Phase 2)Study completedNCT00390325
What this trial is testing

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Who this might be right for
Hereditary Thyroid Gland Medullary CarcinomaLocally Advanced Thyroid Gland Medullary CarcinomaMultiple Endocrine Neoplasia Type 2A+8 more
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Study completedNCT02114658
What this trial is testing

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Who this might be right for
Thyroid Carcinoma
Bayer 18
Next Page